Science Hub
Welcome to Novo Nordisk Science Hub
The information on this website is intended for healthcare professionals only and is provided solely for the purpose of scientific exchange. By accessing this website you accept this legal disclaimer and you expressly confirm your status as a healthcare professional.
This website is not country specific and may therefore contain information that is not applicable to your country. The website is not intended to provide medical advice and/or treatment guidance. Therefore, before prescribing any product, always refer to information approved by regulatory authorities in your country such as the prescribing information and/or the Summary of Product Characteristics. Novo Nordisk accepts no liability for the accuracy, completeness or use of information on this website, and disclaims any liability to update the information contained on this website.
Dr Stephen Harrison is a Visiting Professor of Hepatology at the Radcliffe Department of Medicine, University of Oxford. He currently serves as the Medical Director for Pinnacle Clinical Research and the President of Summit Clinical Research. Dr Harrison earned his medical degree from the University of Mississippi School of Medicine, Jackson, MI, USA. He completed his internal medicine residency and gastroenterology fellowship at Brooke Army Medical Center, Houston, TX, USA and a 4th year advanced liver disease fellowship at Saint Louis University, St Louis, MO, USA. He is board certified in both internal medicine and gastroenterology.
Dr Harrison is internationally known for studies in non-alcoholic fatty liver disease /non-alcoholic steatohepatitis. He is the author of over 300 peer reviewed publications and has an H Index of 88.
Naim Alkhouri
Arizona Liver Health, Phoenix, AZ, USA
Dr Naim Alkhouri is the Chief Medical Officer, Chief of Transplant Hepatology, and Director of the Fatty Liver Program at Arizona Liver Health in Phoenix, AZ, USA.
He has previously served as Director of the Metabolic Health Center at the Texas Liver Institute, San Antonio, TX, USA, and Associate Professor of Medicine and Pediatrics at the University of Texas Health, San Antonio, TX, USA. Dr Alkhouri completed his Gastroenterology and Transplant Hepatology training at the renowned Cleveland Clinic in Cleveland, OH, USA, where he was also appointed Assistant Professor of Medicine and Director of the Metabolic Liver Disease Clinic in the Digestive Disease and Surgery Institute.
Dr Alkhouri's special interests include nonalcoholic fatty liver disease (NAFLD), metabolic liver diseases, viral hepatitis, autoimmune hepatitis, alpha-1 antitrypsin deficiency and liver transplantation. He is a key opinion leader in the field of non-alcoholic steatohepatitis (NASH) therapeutics and an advisor/consultant to many pharmaceutical and biomarker development companies. He is Principal Investigator on several multicenter global NASH trials, and a member of the American Association for the Study of Liver Diseases (AASLD) NASH Special Interest Group.
Dr Alkhouri is an author of over 200 publications in journals including the New England Journal of Medicine, Lancet, JAMA, Gastroenterology, Hepatology and Journal of Hepatology. Among many research awards, Dr Alkhouri received the American College of Gastroenterology Junior Faculty Development Award to study the analysis of breath volatile organic compounds to diagnose nonalcoholic fatty liver disease.
Read full bio
Manal Abdelmalek
NAFLD Clinical Research Program Division of Gastroenterology & Hepatology Mayo Clinic, Rochester, MN, USA
Dr Manal Abdelmalek is a Professor of Medicine, Director of the Hepatobiliary Interest Group and Non-alcoholic Fatty Liver Disease (NAFLD) Clinical Research Program at Mayo Clinic, Rochester, Minnesota, USA.
Her clinical and research area of interest is focused on NAFLD/NASH, associated risk factors for disease acquisition and progression, and the discovery of novel approaches to treatment. She has expertise in clinical-translational research, the design and conduct of clinical trials (investigator-initiated, industry sponsored and National Institutes of Health (NIH)-funded clinical studies evaluating new therapies and biomarkers for NAFLD and NASH) and is the lead Principal Investigator on several multicenter global studies. Dr Abdelmalek is a key opinion leader in the field of NASH therapeutics, a member of the Liver Forum, and advisor/consultant to many industries, the US Food and Drug Administration, and biomarker development companies in the area of diagnostics and therapeutics for NASH. Dr Abdelmalek is a Fellow of the American College of Physicians, American College of Gastroenterology and American Association for the Study of Liver Disease (where she is a member of the Global Outreach and Engagement Committee, and past member of the Clinical Research Committee). She is a steering committee member of the NIH Liver Cirrhosis Network and a former 16-year member of the NASH Clinical Research Network (NASH CRN). Dr Abdelmalek has published more than 200 manuscripts and currently serves as an Associate Editor of Hepatology, the official journal of the AASLD.
Read full bio